GlassScriptPhysician profile
Mitchell Elliott Cohen
NPI 1023002813
$10,726.06
in general payments reported to CMS, 2019-2025
58 companies · $1,888 in 2025
The $1,888 reported for 2025 was more than what 75% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,868 · 2020: $1,179 · 2021: $1,372 · 2022: $1,392 · 2023: $1,135 · 2024: $1,893 · 2025: $1,888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,898 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,897.87 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,424.21 | 2019-2025 | Botox, Ubrelvy |
| Amgen INC. | $1,243.37 | 2019-2025 | Repatha, Repatha, Otezla |
| Abbott Laboratories | $896.59 | 2019-2025 | Aveir, Freestyle Libre 3, Gallant |
| Lilly USA, LLC | $764.31 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $709.24 | 2019-2025 | Breztri, Farxiga, Fasenra |
| Novo Nordisk INC | $659.96 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $364.18 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $340.31 | 2019-2025 | Tradjenta, Synjardy, Jardiance |
| Medtronic, INC. | $313.48 | 2021-2025 | Azure Xt Dr Mri Surescan, Flexcath Advance, Minimed 780g |
| Dexcom, INC. | $306.85 | 2019-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $278.69 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $263.82 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $221.90 | 2019-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $216.83 | 2019-2022 | |
| Insulet Corporation | $184.99 | 2019-2024 | Omnipod |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.